|
F. Hoffmann-La Roche Ltd.: Raising the Bar - Expanding Expectations in HIV Therapy |
SUSA7 |
|
| Type: |
|
| Venue: |
Parkside Auditorium |
|
|
| Time: |
17:00 - 19:00, Sunday, 22.07.2007 |
| Code: |
SUSA7 |
|
|
|
|
|
Roche is committed to discovering innovative therapies and diagnostics to improve the wellbeing of people living with HIV. In 1995 Roche obtained approval for the first protease inhibitor, Invirase® (saquinavir). With the availability of Fuzeon® (enfuvirtide), the first fusion inhibitor, Roche is helping more patients achieve an undetectable viral load (<50 copies/ml). For more information about Roche in HIV, please visit our website www.roche-hiv.com
Media Contact: Janet Kettels
Tel: +1 862 596 9084
Email: janet.kettels@roche.com
|
|
Presentations in this session:
SUSA701
Powerpoint (2.32 MB) | First-line therapy: Fine-tuning treatment decisions in an era of choice
Sharon Walmsley, University of Toronto, Canada
|
SUSA702
Powerpoint (2.01 MB) | Differentiating boosted PIs in ARV-naive patients: Comparative study results
François Raffi, University of Nantes, France
|
SUSA703
Powerpoint (1.39 MB) | Getting to undetectable: The era of choice extends to treatment-experienced patients
Calvin Cohen, Community Research Initiative of New England, United States
|
SUSA704
Powerpoint (1.39 MB) | Protect success: Optimal use of newer ARVs in experienced patients
Cristina Mussini, Azienda Policlinico, Italy
|
|